NCT04926987

Brief Summary

In this study, the single-cell transcriptome sequencing technology was used to study the transcriptome differences at the single-cell level in normal human brain, aging human brain, and epileptic brain.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jun 2020

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2020

Completed
12 months until next milestone

First Submitted

Initial submission to the registry

May 29, 2021

Completed
17 days until next milestone

First Posted

Study publicly available on registry

June 15, 2021

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2022

Completed
Last Updated

June 15, 2021

Status Verified

June 1, 2021

Enrollment Period

2.6 years

First QC Date

May 29, 2021

Last Update Submit

June 14, 2021

Conditions

AgingEpilepsyTrauma, Brain

Keywords

Single-Cell Analysisagingepilepsytrauma brain

Outcome Measures

Primary Outcomes (1)

  • single-cell RNA sequencing

    single-cell RNA sequencing resultes of brain sample

    1 Day of surgery

Interventions

brain tissue single-cell sequencingOTHER

Using single-cell sequencing to study the brain tissue single-cell transcriptome difference in aging, epilepsy, and mental disorders

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

1. Craniocerebral injury patients needing operative treatment 2. Treatment-resistant epilepsy patients needing resection surgery.

You may qualify if:

  • Craniocerebral injury patients needing operative treatment
  • Treatment-resistant epilepsy patients needing resection surgery

You may not qualify if:

  • Vital signs unstable
  • Pregnancy
  • Tumor
  • Incomplete medical history, imaging and clinical diagnosis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

2ndAffiliated Hospital, School of Medicine, Zhejiang University

Hangzhou, Zhejiang, China

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Brain tissue

MeSH Terms

Conditions

EpilepsyBrain Injuries, Traumatic

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesBrain InjuriesCraniocerebral TraumaTrauma, Nervous SystemWounds and Injuries

Study Officials

  • Jianmin Zhang, M.D

    Department of Neurosurgery

    STUDY CHAIR

  • Junming Zhu, M.D

    Department of Neurosurgery

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Jianmin Zhang, M.D

CONTACT

86-13805722695zjm135@zju.edu.cn

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 29, 2021

First Posted

June 15, 2021

Study Start

June 1, 2020

Primary Completion

December 30, 2022

Study Completion

December 30, 2022

Last Updated

June 15, 2021

Record last verified: 2021-06

Locations

CN(1)